Matthew Oberley, Chief Clinical Officer Caris Life Sciences, shared a post on LinkedIn:
“Please join our upcoming webinar discussing the use of AI in diagnosis.
Getting Lung Squamous Cell Carcinoma (SCC) Right: Why Primary Site Determination Changes the Plan.
Overview
The diagnostic consequences for a ‘primary lung SCC’ versus ‘metastatic SCC from another origin’ can shift guideline-driven therapy choices and clinical trial eligibility. This webinar reviews An AI Approach to Differentiating Lung Squamous Cell Carcinoma From Metastases of Other Origins, which asks whether an AI-assisted approach integrated into routine molecular profiling can reliably distinguish primary lung SCC from metastases of other origins.
We’ll connect those findings to real-world practice and show how Caris’ integrated platform – broad molecular profiling with AI tissue-of-origin support – helps teams align treatment with the most accurate diagnosis.
Speakers
Hassan Ghani – Physician Scientist at Caris Life Sciences
Anthony Karnezis – Associate Professor, Lead – Gynecologic Pathology Service, Director, Gynecologic and Breast Pathology Fellowship at University of California Davis Pathology
Registration Required.
All attendees, internal and external, must register in advance. Please register:
Webinar Recording.
For those unable to attend live, a recording will be available on the Caris Webinar website after the event.”
Other Articles Featuring Matthew Oberley On OncoDaily.